Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Vertex's $420M+ preclinical play combines Exonics' SingleCut CRISPR with expanded CRISPR Therapeutics collaboration to establish a DMD/DM1 gene-editing…
Nonprofit CureDuchenne is encouraged to see gene editing for Duchenne advance through Vertex's acquisition of Exonics Therapeutics, validating the gene editing…
The transactions reflect optimistic sentiment around combining complementary IP and expertise to address DMD/DM1, with Sarepta's controversial 2016 Exondys…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Vertex acquired Exonics Therapeutics for $245M upfront plus up to $755M in milestones (~$1B total). Concurrently expanded its collaboration with CRISPR Therapeutics on DMD/DM1 with a $175M upfront and $25M equity investment. Adds CRISPR gene editing platform for Duchenne and myotonic dystrophy.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated / Exonics Therapeutics (this deal) | 2019 | $1.0B | — |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Vertex Pharmaceuticals Incorporated / Semma Therapeutics Inc. | 2019 | $950M | 86 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG | 2015 | $2.6B | 85 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Vertex Pharmaceuticals Incorporated / Crinetics Pharmaceuticals, Inc. | 2026 | $10.0B | 68 |
← Browse all deals · How we score deals
More: 2019 deals · Vertex Pharmaceuticals Incorporated deals · Neurology deals